首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1536063

複合藥局市場 - 分產品（口服、腸胃外、局部、眼科、鼻腔、直腸、耳科）治療領域（疼痛管理、荷爾蒙替代）、應用、複合類型、無菌、配銷通路、全球預測 2024 - 2032

Compounding Pharmacies Market - By Product (Oral, Parenteral, Topical, Ophthalmic, Nasal, Rectal, Otic) Therapeutic Area (Pain Management, Hormone Replacement), Application, Compounding Type, Sterility, Distribution Channel, Global Forecast 2024 - 2032

出版日期: 2024年06月28日 | 出版商:

Global Market Insights Inc. | 英文 252 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

在製藥創新和研究的推動下，2024 年至 2032 年間，全球複合藥房市場複合年成長率將超過 5.6%。持續的研發努力發現了新穎的複合技術和定製藥物，為具有獨特需求的患者提供了更多的治療選擇。根據美國 FDA 2023 年 1 月的報告，2022 年超過 60% 的新藥申請涉及創新配方，凸顯了正在進行的藥物研究在推進複合技術和擴大個人化藥物機會方面的重要作用。

這些進步使藥劑師能夠創造出更有效、個人化的配方，以滿足特定的醫療狀況、過敏和劑量要求。隨著新技術和方法的出現，複方藥局提供了創新的解決方案。前沿研究的整合增強了醫療保健提供者和患者之間的信任，增強了對定製藥物的需求。

整個複方製藥業根據產品、治療領域、應用、複方類型、無菌、配銷通路和地區進行分類。

由於需要為嬰兒和兒童提供精確、客製化的藥物，到 2032 年，父母細分市場將出現相當大的複合年成長率。標準劑量和配方通常不適合該群體，需要客製化解決方案。複方藥房可以創造特定的劑型，例如液體或經皮凝膠，更容易讓兒童攝入和吸收。此外，它們可以排除過敏原或不耐受物質，確保安全性和有效性。這種個人化滿足了兒科患者獨特的醫療需求，導致家長對複方藥局的依賴日益成長。

到 2032 年，由於需要標準藥物無法提供的個人化荷爾蒙療法，荷爾蒙替代細分市場將佔據顯著的複合藥房市場佔有率。患者通常需要根據其獨特的生理需求量身定做特定的荷爾蒙組合和劑量，而複方藥房可以提供這些組合和劑量。此外，他們可以配製生物相同的激素，密切模仿人體的天然激素，改善治療效果並減少副作用。這種客製化提高了患者滿意度和治療效果，使複方藥房成為有效荷爾蒙替代療法的重要資源。

由於對個人化醫療的日益關注以及滿足大規模生產藥物無法滿足的患者需求的需要，歐洲複合藥房市場將從 2024 年到 2032 年以驚人的複合年成長率蓬勃發展。慢性疾病和複雜醫療狀況的激增需要定製藥物。對複合實踐的監管支持，加上醫療保健提供者對客製化治療的好處的認知不斷提高，刺激了需求。該地區人口老化以及他們對個人化和有效治療解決方案的需求將促進歐洲市場的成長。

產業生態系統分析
產業影響力
- 成長動力
  - 全球老年人口不斷增加，預期壽命提高
  - 已開發地區越來越多採用客製化醫療
  - 全球藥品短缺
  - 複方藥物的好處
- 產業陷阱與挑戰
  - 已開發經濟體缺乏熟練的實驗室技術人員和藥劑師
  - 設備成本高、無菌環境維護成本高
  - 不穩定的監管環境
成長潛力分析
監管環境
- 美國
- 歐洲
- 澳洲
報銷版圖
- 美國
- 歐洲
- 澳洲
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司矩陣分析
主要市場參與者的競爭分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按產品分類，2021 - 2032 年

主要趨勢
口服
- 固體製劑
  - 平板電腦
  - 膠囊
  - 顆粒劑
  - 粉末
  - 其他固體製劑
- 液體製劑
  - 解決方案
  - 暫停
  - 乳液
  - 糖漿
  - 其他液體製劑
專題
- 藥膏
- 乳霜
- 凝膠
- 膏體
- 其他局部產品
直腸
- 栓劑
- 灌腸
- 其他直腸產品
注射用
- 大容量注射劑 (LVP)
- 小容量注射劑 (LVP)
鼻腔
眼科
奧迪克

第 6 章：市場估計與預測：按治療領域，2021 - 2032 年

主要趨勢
疼痛管理
荷爾蒙替代品
皮膚科應用
特殊藥物
營養補充品
其他治療領域

第 7 章：市場估計與預測：按應用分類，2021 - 2032

主要趨勢
成人
老年科
獸醫
兒科

第 8 章：市場估計與預測：按複利類型，2021 - 2032

主要趨勢
藥物成分改變（PIA）
目前無法使用的藥品製造 (CUPM)
藥物劑量改變（PDA）
其他複合類型

第 9 章：市場估計與預測：按無菌性分類，2021 - 2032 年

主要趨勢
無菌劑型
非無菌劑型

第 10 章：市場估計與預測：按配銷通路分類，2021 - 2032 年

主要趨勢
醫院藥房
調配藥房
其他分銷管道

第 11 章：市場估計與預測：按地區，2021 - 2032

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 波蘭
- 荷蘭
- 瑞典
- 比利時
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 新加坡
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 卡達
- 中東和非洲其他地區

第 12 章：公司簡介

B. Braun Melsungen AG
Clinigen Group PLC
Dougherty's Pharmacy, Inc.
Fagron NV
Fresenius Kabi AG
ITC Compounding Pharmacy
Institutional Pharmacy Solutions, LLC
Lorraine's Pharmacy
McGuff Compounding Pharmacy Services
Nephron Pharmaceuticals Corporation
Pencol Compounding Pharmacy
Rx3 Compounding Pharmacy
Triangle Compounding Pharmacies
Valor Compounding Pharmacy, Inc.
Wedgewood Village Pharmacy, Inc.

簡介目錄

Product Code: 749

Global Compounding Pharmacies Market will experience over 5.6% CAGR between 2024 and 2032, ushered by pharmaceutical innovation and research. Continuous R&D efforts have lead to the discovery of novel compounding techniques and customized medications, enhancing treatment options for patients with unique needs. According to the U.S. FDA report in January 2023, over 60% of new drug applications in 2022 involved innovative formulations, highlighting the significant role of ongoing pharmaceutical research in advancing compounding techniques and expanding opportunities for personalized medications.

These advancements enable pharmacists to create more effective, personalized formulations that address specific medical conditions, allergies, and dosage requirements. As new technologies and methods emerge, compounding pharmacies provide innovative solutions. The integration of cutting-edge research fosters trust among healthcare providers and patients, bolstering the demand for tailored medications.

The overall compounding pharmacies industry is classified based on product, therapeutic area, application, compounding type, sterility, distribution channel, and region.

The parental segment will witness a considerable CAGR through 2032, owing to the need for precise, tailored medications for infants and children. Standard dosages and formulations often do not suit this group, necessitating customized solutions. Compounding pharmacies can create specific dosage forms, such as liquids or transdermal gels, which are easier for children to ingest and absorb. Additionally, they can exclude allergens or intolerant substances, ensuring safety and efficacy. This personalization meets the unique medical needs of pediatric patients, ushering in the growing reliance on compounding pharmacies in the parental segment.

The hormone replacement segment will garner a noteworthy compounding pharmacies market share by 2032, because of the need for personalized hormone therapies that standard medications cannot provide. Patients often require specific hormone combinations and dosages tailored to their unique physiological needs, which compounding pharmacies can create. Additionally, they can formulate bio identical hormones, closely mimicking the body's natural hormones, improving treatment outcomes and reducing side effects. This customization enhances patient satisfaction and treatment efficacy, making compounding pharmacies an essential resource for effective hormone replacement therapy.

Europe compounding pharmacies market will thrive at a remarkable CAGR from 2024 to 2032, due to an increasing focus on personalized medicine and the need to address patient requirements that mass-produced drugs cannot meet. The upsurge in chronic illnesses and complex medical conditions necessitates customized drugs. Regulatory support for compounding practices, coupled with a heightened awareness among healthcare providers about the benefits of tailored treatments, fuels the demand. The aging population in the region, along with their need individualized & effective therapeutic solutions will augment the market growth in Europe.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rising geriatric population and improved life expectancy across the globe
  - 3.2.1.2 Rising adoption of customized medicine in the developed regions
  - 3.2.1.3 Shortage of drugs across the globe
  - 3.2.1.4 Benefits of compounded medication
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Lack of skilled lab technicians and pharmacists in developed economies
  - 3.2.2.2 High cost of equipment and maintenance of sterile environment
  - 3.2.2.3 Volatile regulatory scenario
3.3 Growth potential analysis
3.4 Regulatory landscape
- 3.4.1 U.S.
- 3.4.2 Europe
- 3.4.3 Australia
3.5 Reimbursement landscape
- 3.5.1 U.S.
- 3.5.2 Europe
- 3.5.3 Australia
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Oral
- 5.2.1 Solid preparations
  - 5.2.1.1 Tablets
  - 5.2.1.2 Capsules
  - 5.2.1.3 Granules
  - 5.2.1.4 Powder
  - 5.2.1.5 Other solid preparations
- 5.2.2 Liquid preparations
  - 5.2.2.1 Solutions
  - 5.2.2.2 Suspension
  - 5.2.2.3 Emulsion
  - 5.2.2.4 Syrup
  - 5.2.2.5 Other liquid preparations
5.3 Topical
- 5.3.1 Ointments
- 5.3.2 Creams
- 5.3.3 Gels
- 5.3.4 Pastes
- 5.3.5 Other topical products
5.4 Rectal
- 5.4.1 Suppositories
- 5.4.2 Enema
- 5.4.3 Other rectal products
5.5 Parenteral
- 5.5.1 Large volume parenterals (LVPs)
- 5.5.2 Small volume parenterals (LVPs)
5.6 Nasal
5.7 Ophthalmic
5.8 Otic

Chapter 6 Market Estimates and Forecast, By Therapeutic Area, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Pain management
6.3 Hormone replacement
6.4 Dermatology applications
6.5 Specialty drugs
6.6 Nutritional supplements
6.7 Other therapeutic areas

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Adult
7.3 Geriatric
7.4 Veterinary
7.5 Pediatric

Chapter 8 Market Estimates and Forecast, By Compounding Type, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Pharmaceutical ingredient alteration (PIA)
8.3 Currently unavailable pharmaceutical manufacturing (CUPM)
8.4 Pharmaceutical dosage alteration (PDA)
8.5 Other compounding types

Chapter 9 Market Estimates and Forecast, By Sterility, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 Sterile dosage form
9.3 Non sterile dosage form

Chapter 10 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

10.1 Key trends
10.2 Hospital pharmacies
10.3 Compounding pharmacies
10.4 Other distribution channels

Chapter 11 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

11.1 Key trends
11.2 North America
- 11.2.1 U.S.
- 11.2.2 Canada
11.3 Europe
- 11.3.1 Germany
- 11.3.2 UK
- 11.3.3 France
- 11.3.4 Spain
- 11.3.5 Italy
- 11.3.6 Poland
- 11.3.7 Netherlands
- 11.3.8 Sweden
- 11.3.9 Belgium
- 11.3.10 Rest of Europe
11.4 Asia Pacific
- 11.4.1 China
- 11.4.2 Japan
- 11.4.3 India
- 11.4.4 Australia
- 11.4.5 South Korea
- 11.4.6 Singapore
- 11.4.7 Rest of Asia Pacific
11.5 Latin America
- 11.5.1 Brazil
- 11.5.2 Mexico
- 11.5.3 Argentina
- 11.5.4 Rest of Latin America
11.6 Middle East and Africa
- 11.6.1 South Africa
- 11.6.2 Saudi Arabia
- 11.6.3 UAE
- 11.6.4 Qatar
- 11.6.5 Rest of Middle East and Africa